Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-Alfa2b With or Without Thalidomide in Advanced Renal Cell Carcinoma
NCT00005966Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2000
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of thalidomide in renal cell carcinoma (RCC) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Overall Survival at 24 weeks and Progression-Free Survival at 24 weeks. Started Oct 2000; status: completed.
02
Drugs
thalidomide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00005966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005966.